We continually prove it’s possible to invent and advance affordable and effective medicines that prevent and treat diseases of poverty, like HIV, malaria, diarrheal disease, and infections—and to get them safely to people who need them.
How PATH is advancing new effective and affordable treatments for diarrhea and the underlying enteric infections that cause it.
Research in Uganda and elsewhere has shown that women are able to self-administer DMPA-SC safely and effectively, that they like doing so, and that self-injection helps support women to continue using injectable contraception.
The DMPA-SC Evidence to Practice workshop was held in May 2018 with the goal of increasing voluntary and high-quality access to DMPA-SC within a wide range of contraceptive methods.
Several thousands of health workers around the world have been trained to safely provide DMPA-SC injections in clinics, community locations, and villages, and even to support women to self-inject.
Family planning advocates can ensure that a country’s policies and funding promote access to all contraceptive options, so women can make an informed and voluntary choice. The Advocacy Pack for Subcutaneous DMPA was designed for advocates around the globe to help increase access to this new injectable contraceptive option.
A new initiative led by PATH in partnership with John Snow, Inc., the DMPA-SC Access Collaborative works with ministries of health and partners to strengthen scale-up and build a robust global market for DMPA-SC, as an important new addition to the full range of contraceptive options.